Dallas, TX -- (SBWIRE) -- 02/03/2015 -- The report "Anaplastic Thyroid Cancer – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Anaplastic Thyroid Cancer. Anaplastic thyroid cancer is the least common type of thyroid cancer. Anaplastic thyroid cancer often arises within a more differentiated thyroid cancer or even within a goiter. Anaplastic thyroid cancer grows very rapidly and is an invasive type of thyroid cancer. The cause of anaplastic thyroid cancer is unknown. Signs & symptoms include cough, coughing up blood, difficulty swallowing, hoarseness or changing voice, loud breathing and lower neck lump.

Complete Report is Available
http://www.rnrmarketresearch.com/anaplastic-thyroid-cancer-pipeline-review-h1-2015-market-report.html

It also reviews key players involved in the therapeutic development for Anaplastic Thyroid Cancer and special features on late-stage and discontinued projects. Companies discussed in this Anaplastic Thyroid Cancer Pipeline Review H1 2015 report include Daiichi Sankyo Company, Limited, Exelixis, Inc., Genelux Corporation, GlaxoSmithKline plc, Immune Pharmaceuticals, Ltd., Novartis AG, OXiGENE, Inc., Plexxikon Inc., Takeda Oncology.

The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Order a Purchase copy of this report
http://www.rnrmarketresearch.com/contacts/purchase?rname=269609
(This is a premium report priced at US$2000 for a single user License.)

Table of Contents

List of Tables

Number of Products under Development for Anaplastic Thyroid Cancer, H1 2015 8
Number of Products under Development for Anaplastic Thyroid Cancer - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Anaplastic Thyroid Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 16
Anaplastic Thyroid Cancer - Pipeline by Exelixis, Inc., H1 2015 17
Anaplastic Thyroid Cancer - Pipeline by Genelux Corporation, H1 2015 18
Anaplastic Thyroid Cancer - Pipeline by GlaxoSmithKline plc, H1 2015 19
Anaplastic Thyroid Cancer - Pipeline by Immune Pharmaceuticals, Ltd., H1 2015 20
Anaplastic Thyroid Cancer - Pipeline by Novartis AG, H1 2015 21
Anaplastic Thyroid Cancer - Pipeline by OXiGENE, Inc., H1 2015 22
Anaplastic Thyroid Cancer - Pipeline by Plexxikon Inc., H1 2015 23
Anaplastic Thyroid Cancer - Pipeline by Takeda Oncology, H1 2015 24
Assessment by Monotherapy Products, H1 2015 25
Assessment by Combination Products, H1 2015 26
Number of Products by Stage and Target, H1 2015 28
Number of Products by Stage and Mechanism of Action, H1 2015 30
Number of Products by Stage and Route of Administration, H1 2015 32
Number of Products by Stage and Molecule Type, H1 2015 34
Anaplastic Thyroid Cancer Therapeutics - Recent Pipeline Updates, H1 2015 56
Anaplastic Thyroid Cancer - Dormant Projects, H1 2015 79

Inquiry before Buying
http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=269609
(This is a premium report priced at US$2000 for a single user License.)

List of Figures

Number of Products under Development for Anaplastic Thyroid Cancer, H1 2015 8
Number of Products under Development for Anaplastic Thyroid Cancer - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 12
Assessment by Monotherapy Products, H1 2015 25
Number of Products by Top 10 Targets, H1 2015 27
Number of Products by Stage and Top 10 Targets, H1 2015 27
Number of Products by Top 10 Mechanism of Actions, H1 2015 29
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 29
Number of Products by Top 10 Routes of Administration, H1 2015 31
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 31
Number of Products by Top 10 Molecule Types, H1 2015 33
Number of Products by Stage and Top 10 Molecule Types, H1 2015 33

Explore more reports on Pharmaceuticals industry
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals

About RnRMarketResearch.com
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.